FI20165730A - Sydän- ja verisuonitauteihin liittyvien riskien arviointimenetelmä - Google Patents

Sydän- ja verisuonitauteihin liittyvien riskien arviointimenetelmä

Info

Publication number
FI20165730A
FI20165730A FI20165730A FI20165730A FI20165730A FI 20165730 A FI20165730 A FI 20165730A FI 20165730 A FI20165730 A FI 20165730A FI 20165730 A FI20165730 A FI 20165730A FI 20165730 A FI20165730 A FI 20165730A
Authority
FI
Finland
Prior art keywords
risk
crp
mmp
cardiovascular
disease
Prior art date
Application number
FI20165730A
Other languages
English (en)
Swedish (sv)
Other versions
FI127416B (fi
Inventor
Pirkko Pussinen
Timo Sorsa
Veikko Salomaa
Juuso Juhila
Armi Korvuo
Sinikka Tiisala
Original Assignee
Oy Medix Biochemica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FI20165730A priority Critical patent/FI127416B/fi
Application filed by Oy Medix Biochemica Ab filed Critical Oy Medix Biochemica Ab
Priority to JP2019517382A priority patent/JP2019535012A/ja
Priority to PCT/FI2017/050680 priority patent/WO2018060556A1/en
Priority to KR1020197012202A priority patent/KR20190061040A/ko
Priority to US16/337,440 priority patent/US20190234965A1/en
Priority to BR112019006014A priority patent/BR112019006014A2/pt
Priority to CA3037542A priority patent/CA3037542A1/en
Priority to EP17855075.2A priority patent/EP3519819A4/en
Priority to CN201780059983.8A priority patent/CN109791143A/zh
Publication of FI20165730A publication Critical patent/FI20165730A/fi
Application granted granted Critical
Publication of FI127416B publication Critical patent/FI127416B/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
FI20165730A 2016-09-29 2016-09-29 Sydän- ja verisuonitauteihin liittyvien riskien arviointimenetelmä FI127416B (fi)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FI20165730A FI127416B (fi) 2016-09-29 2016-09-29 Sydän- ja verisuonitauteihin liittyvien riskien arviointimenetelmä
PCT/FI2017/050680 WO2018060556A1 (en) 2016-09-29 2017-09-27 Method for determining risks associated with cardiovascular diseases
KR1020197012202A KR20190061040A (ko) 2016-09-29 2017-09-27 심혈관 질환과 관련된 위험을 결정하는 방법
US16/337,440 US20190234965A1 (en) 2016-09-29 2017-09-27 Method for determining risks associated with cardiovascular diseases
JP2019517382A JP2019535012A (ja) 2016-09-29 2017-09-27 心血管疾患に関連するリスクを決定する方法
BR112019006014A BR112019006014A2 (pt) 2016-09-29 2017-09-27 métodos para determinar riscos associados com doenças cardiovasculares e para construir um modelo de prognóstico de risco, e, uso de detecção de mmp-8 e crp.
CA3037542A CA3037542A1 (en) 2016-09-29 2017-09-27 Method for determining risks associated with cardiovascular diseases
EP17855075.2A EP3519819A4 (en) 2016-09-29 2017-09-27 METHOD FOR DETERMINING RISKS RELATING TO CARDIOVASCULAR DISEASES
CN201780059983.8A CN109791143A (zh) 2016-09-29 2017-09-27 确定与心血管疾病相关的风险的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20165730A FI127416B (fi) 2016-09-29 2016-09-29 Sydän- ja verisuonitauteihin liittyvien riskien arviointimenetelmä

Publications (2)

Publication Number Publication Date
FI20165730A true FI20165730A (fi) 2018-03-30
FI127416B FI127416B (fi) 2018-05-31

Family

ID=61760181

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20165730A FI127416B (fi) 2016-09-29 2016-09-29 Sydän- ja verisuonitauteihin liittyvien riskien arviointimenetelmä

Country Status (9)

Country Link
US (1) US20190234965A1 (fi)
EP (1) EP3519819A4 (fi)
JP (1) JP2019535012A (fi)
KR (1) KR20190061040A (fi)
CN (1) CN109791143A (fi)
BR (1) BR112019006014A2 (fi)
CA (1) CA3037542A1 (fi)
FI (1) FI127416B (fi)
WO (1) WO2018060556A1 (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111856009A (zh) * 2020-02-28 2020-10-30 安徽大千生物工程有限公司 一种基于胶乳增强免疫比浊法测定mmp-3的试剂盒及其制备使用方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108334417B (zh) * 2018-01-26 2021-03-02 创新先进技术有限公司 确定数据异常的方法和装置
CN111710425A (zh) * 2020-06-19 2020-09-25 复旦大学附属中山医院 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
KR102362951B1 (ko) 2020-08-13 2022-02-14 연세대학교 원주산학협력단 프로칼시토닌 대 ｃ­반응성 단백질의 비율을 이용한 허혈성 뇌졸중의 단기 사망률 예측 방법
CN113488174A (zh) * 2021-08-05 2021-10-08 新乡医学院第一附属医院 用于预测急性脑血管病发生风险的方法
CN115862853B (zh) * 2022-08-12 2023-11-21 内蒙古自治区综合疾病预防控制中心 一种前列腺癌患者的心血管疾病发生风险的评估方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305235A1 (en) * 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
US9359633B2 (en) * 2007-11-05 2016-06-07 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
WO2013190041A1 (en) * 2012-06-22 2013-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the survival time of post acute myocardial infarction patients
EP2835641A1 (en) * 2013-08-09 2015-02-11 Inotrem Methods and kits for predicting the risk of having a cardiovascular disease or event
FI127924B (fi) * 2014-02-27 2019-05-31 Oy Medix Biochemica Ab Menetelmä mmp-8 aktivoinnin määrittämiseksi

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111856009A (zh) * 2020-02-28 2020-10-30 安徽大千生物工程有限公司 一种基于胶乳增强免疫比浊法测定mmp-3的试剂盒及其制备使用方法

Also Published As

Publication number Publication date
CN109791143A (zh) 2019-05-21
WO2018060556A1 (en) 2018-04-05
KR20190061040A (ko) 2019-06-04
BR112019006014A2 (pt) 2019-06-25
US20190234965A1 (en) 2019-08-01
FI127416B (fi) 2018-05-31
EP3519819A4 (en) 2020-03-25
JP2019535012A (ja) 2019-12-05
EP3519819A1 (en) 2019-08-07
CA3037542A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
FI20165730A (fi) Sydän- ja verisuonitauteihin liittyvien riskien arviointimenetelmä
WO2015025187A8 (en) Method and device for improving prediction and detection of change in a physiological condition
ATE543435T1 (de) System zum nachweis von stürzen
WO2016046640A3 (en) Methods for predicting drug responsiveness
WO2013113012A3 (en) Methods for profiling and quantitating cell-free rna
WO2016064562A3 (en) Adaptive threshold manipulation for movement detecting sensors
GB2557030A8 (en) Method and apparatus for identifying fluids behind casing
FR2996673B1 (fr) Capteur capacitif pour la detection de presence d'un objet et/ou d'un individu.
WO2015100177A3 (en) Neural watchdog
JP2013525762A5 (fi)
JP2016507098A5 (fi)
WO2014085826A3 (en) Method for evaluation of presence of or risk of colon tumors
WO2015132691A3 (en) Method for deploying sensors
PE20140367A1 (es) Sistema de advertencia de sismos
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
MA52952A (fr) Méthode de détection permettant la détection d'un analyte dans un échantillon
JP2017508950A5 (fi)
WO2015126935A3 (en) Automated profiling of the hardness of wood
NO20180408A1 (en) Detection of Influx and Loss of Circulation
JP2016505840A5 (fi)
FR2977674B1 (fr) Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule
WO2014083520A3 (en) Assays for detecting neutralizing autoantibodies to biologic therapy
JP2017522939A5 (fi)
WO2015070191A3 (en) Systems and methods for detection of genomic variants
RU2016107954A (ru) Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 127416

Country of ref document: FI

Kind code of ref document: B

MM Patent lapsed